## Glucagon Reduction by Tirzepatide

### What is the evidence that tirzepatide reduces glucagon in a glucose-dependent manner?

Jun 4, 4:56 PM

I'll search for studies on tirzepatide's glucagon suppression mechanisms, particularly the glucose-dependency of that effect.

### The mechanistic basis

The glucose-dependent glucagon suppression attributed to tirzepatide derives primarily from its GLP-1 receptor component. GLP-1 is well established to inhibit alpha-cell glucagon secretion in a glucose-dependent fashion — it suppresses glucagon at or above normal fasting glucose concentrations but does not do so (or does so minimally) at hypoglycemic glucose levels, which is why GLP-1 receptor agonists carry minimal hypoglycemia risk as monotherapy. Tirzepatide's GIP component complicates this picture: native GIP actually stimulates glucagon secretion (glucagonotropic) at low glucose concentrations, which is a physiologically important counterbalance during hypoglycemia. A 2019 review in _IJMS_ by Mathiesen et al. covers this incretin physiology in detail, noting that while GLP-1 inhibits glucagon above normal fasting concentrations, GIP acts glucagonotropically at low glucose. The implication for tirzepatide is that its net glucagon suppression at euglycemic and hyperglycemic levels should be glucose-dependent, with the GIP component potentially attenuating suppression at low glucose (preserving the hypoglycemia counter-response).

### Clinical evidence of glucagon suppression

The most direct pharmacodynamic evidence comes from a phase 1 RCT by Heise, Mari, DeVries et al. published in _Lancet Diabetes & Endocrinology_ (2022, n=117, tirzepatide 15mg vs. semaglutide 1mg vs. placebo). On meal tolerance testing, tirzepatide significantly reduced postprandial glucagon concentrations compared to placebo, with effects greater than semaglutide. A companion analysis by Mather et al. ( _JCEM_, 2024, same 28-week double-blind design) found that tirzepatide significantly reduced both fasting glucagon and total glucagon area under the curve during a mixed-meal tolerance test, with the glucagon AUC reduction significantly greater for tirzepatide than semaglutide. The authors attributed a substantial portion of tirzepatide's superior fasting glucose control to enhanced glucagon suppression alongside improvements in insulin secretion and sensitivity.

The SURPASS J-mono substudy (Yabe et al., _Diabetes Obesity & Metabolism_, 2022) comparing tirzepatide to dulaglutide in Japanese patients with type 2 diabetes also reported reductions in postprandial glucagon.

### Where glucose-dependence is inferred rather than directly shown

An important caveat: the clinical trial evidence above demonstrates that tirzepatide suppresses glucagon (especially postprandially and at elevated fasting glucose levels), and the absence of significant hypoglycemia in trials is consistent with glucose-dependent suppression. But dedicated clamp studies directly demonstrating that tirzepatide's glucagon suppression attenuates at low glucose concentrations — the standard way to formally prove glucose-dependence — are not prominently represented in my search results. The claim is supported by mechanistic inference from GLP-1 receptor pharmacology and by the favorable hypoglycemia profile in trials, not by a dedicated glucose-concentration–response experiment for glucagon. A 2023 review by Gasbjerg et al. in _Diabetes, Obesity & Metabolism_ raises the additional complication that GIP's glucagonotropic effect at low glucose might be modified by tirzepatide's in vitro receptor pharmacology (biased GLP-1R activation, GIPR downregulation), making the net effect uncertain.

In sum, there is solid clinical evidence that tirzepatide robustly suppresses glucagon, particularly postprandially and in hyperglycemic states, with the effect larger than selective GLP-1 receptor agonism. Glucose-dependence is mechanistically expected and supported by the lack of hypoglycemia, but has not been as rigorously characterized in dedicated titration experiments as the broader claim of glucose-dependent glucagon suppression might suggest.